Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 6/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.33 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.32 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4885369 | 0.92 | KMT2A (0.34) | OPRM1KDM4EMEN1ALDH1A1TSHR | |
| SCHEMBL4889118 | 0.86 | SIGMAR1 (0.36) | KDM4EALDH1A1KMT2ALMNAGAA | |
| SCHEMBL4563480 | 0.85 | HPGD (0.34) | OPRM1MEN1KMT2AOPRD1OPRK1 | |
| SCHEMBL4432781 | 0.85 | NPFFR1 (0.36) | KDM4EMEN1ALDH1A1KMT2AOPRD1 | |
| SCHEMBL4886384 | 0.84 | POLB (0.41) | KDM4EMEN1ALDH1A1TSHRKMT2A | |
| SCHEMBL15808512 | 0.84 | EPHX2 (0.37) | ALDH1A1TSHR | |
| SCHEMBL4880934 | 0.83 | UTS2R (0.38) | MEN1ALDH1A1KMT2A | |
| SCHEMBL4432414 | 0.83 | ASAH1 (0.39) | MEN1TSHRKMT2A | |
| SCHEMBL4430432 | 0.83 | ALDH1A1 (0.35) | KDM4EMEN1ALDH1A1TSHRKMT2A | |
| SCHEMBL4440078 | 0.80 | UTS2R (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8759342-B2 | Benzo[1,4]oxazin-3-one, benzo[1,4]thiazin-3-one and quinolin-2-one urotensin II receptor antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2014-06-24 | — | — | US | claimed |
| US-20080039454-A1 | Urotensin II receptor antagonists | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-02-14 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039454-A1 | Urotensin II receptor antagonists | UTS2R, PLAUR, NTSR2 | OPRM1 557/4885KDM4E 4604/4885MEN1 2791/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.